Publication Name	World Journal of Nephrology
Manuscript ID	23092
Country	Italy

Received	2015-10-20 08:10
Peer-Review Started	2015-10-21 08:58
First Decision by Editorial Office Director
Return for Revision	2015-11-06 11:28
Revised	2015-11-13 00:23
Publication Fee Transferred
Second Decision by Editor	2015-11-23 18:05
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2015-12-04 16:32
Articles in Press	2015-12-04 16:32
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-01-05 09:54
Publish the Manuscript Online	2016-01-06 20:46

ISSN	2220-6124 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Frontier
Article Title	Update on immunoglobulin a nephropathy. Part Ⅱ: Clinical, diagnostic and therapeutical aspects
Manuscript Source	Invited Manuscript
All Author List	Maurizio Salvadori and Giuseppina Rosso
Funding Agency and Grant Number
Corresponding Author	Maurizio Salvadori, MD, Department of Renal Transplantation and Renal Diseases, Careggi University Hospital, viale Pieraccini 18, 50139 Florence, Italy. maurizio.salvadori1@gmail.com
Key Words	IgA nephropathy prevention and control; IgA nephropathy; IgA nephropathy diagnosis; IgA nephropathy prognosis; IgA nephropathy classification; IgA nephropathy therapy
Core Tip	Primary immunoglobulin A nephropathy (IgAN) is the most frequent glomerulonephritis. The IgAN is a relatively benign disease however, the long term prognosis should not be considered mild, because, after 20 years of disease evolution, 25% of the patients are going into chronic renal failure. It is essential to find out the risk factors predicting the evolution to end-stage renal disease (ESRD) and to select those patients who may benefit from immunosuppressive treatment. For all patients, it is essential to have a regular clinical control to check any disease evolution, in order to avoid or delay the disease progression to ESRD.
Publish Date	2016-01-06 20:46
Citation	Salvadori M, Rosso G. Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects. World J Nephrol 2016; 5(1): 6-19
URL	http://www.wjgnet.com/2220-6124/full/v5/i1/6.htm
DOI	http://dx.doi.org/10.5527/wjn.v5.i1.6

Full Article (PDF)	WJN-5-6.pdf
Full Article (Word)	WJN-5-6.doc
Manuscript File	23092-Review.docx
Answering Reviewers	23092-Answering reviewers.pdf
Audio Core Tip	23092-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	23092-Conflict-of-interest statement.pdf
Copyright License Agreement	23092-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	23092-Language certificate.pdf
Peer-review Report	23092-Peer-review(s).pdf
Scientific Misconduct Check	23092-Scientific misconduct check.pdf
Scientific Editor Work List	23092-Scientific editor work list.pdf